Please login to the form below
apixaban
This page shows the latest apixaban news and features for those working in and with pharma, biotech and healthcare.
Pfizer's 2021 revenue predictions soar to $82bn
In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased
Latest news
-
BMS reports strong growth as its Q3 results beat predictions
The drivers of growth were multiple myeloma drug Revlimid (lenalidomide), which saw sales of $3.34bn (up by 11%), blood-thinner Eliquis (apixaban) with $2.41bn (up by 15%) and cancer
-
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... Although BMS maintained at the time that the patent for composition of matter covering apixaban in the
-
Bristol-Myers Squibb’s revenues rise on Celgene acquisition
The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their
-
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls
BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to
-
Vyndaqel a bright spot as Pfizer comes under pressure
ago. Meanwhile, vaccine blockbuster Prevnar also continued its slowdown, but still brought in $1.58bn in the quarter, and anticoagulant Eliquis (apixaban) continued its strong growth with a 21% gain to
More from news
Approximately 9 fully matching, plus 87 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2016
merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).
-
Modern anticoagulants threaten status quo
Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor. ... statistically significant reduction in mortality was also observed in apixaban recipients in this trial.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
PPD expands global product department with new therapeutic area heads
Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
There was also a greater number of generic products. Anticoagulant therapies such as apixaban, rivaroxaban and edoxaban topped the spending charts, while respiratory products such as inhalable treatments for asthma and
-
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
This was followed by anti-coagulant medication (£740 million), where there were notable increases in spending on drugs such as apixaban (up 16 per cent), rivaroxaban (up 5.1 per cent)
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
